OMTX705, a powerful stroma-targeting ADC to treat invasive tumors with low response to immunotherapeutic anti-PD-1 treatments
, , , , , , , , , , and .
ANNALS OF ONCOLOGY (October 2018)43rd ESMO Congress (ESMO), Munich, GERMANY, OCT 19-23, 2018.

  • @unibiblio-4
This publication has not been reviewed yet.

rating distribution
average user rating0.0 out of 5.0 based on 0 reviews
    Please log in to take part in the discussion (add own reviews or comments).